Novartis Japan Files New Drug Application for Agent for Treating Bronchial Asthma.Tokyo, Japan, June 26, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novartis Pharma Japan announced on June 26 that it has filed a new drug application for Xolair for Subcutaneous Injection Noun 1. subcutaneous injection - an injection under the skin injection, shot - the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot" 150mg, its proprietary agent for treating bronchial asthma bronchial asthma n. A condition of the lungs characterized by widespread narrowing of the airways due to spasm of the smooth muscle, edema of the mucosa, and the presence of mucus in the lumen of the bronchi and bronchioles. (BA), with the Ministry of Health, Labor and Welfare. A recombinant humanized monoclonal anti-IgE antibody anti-IgE antibody Allergy medicine An antibody directed against IgE. See Allergy. , Xolair (omalizumab) can exert beneficial effects with a once- or twice-per-month administration. In the recent trials, the agent showed a significant improvement in patients with severe allergic bronchial asthma. Xolair, which was initially approved in the US in July 2003, is currently marketed in 15 countries including the UK, Germany, Canada, Brazil and Australia. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion